參考文獻/References:
[1] CORTINI M,AVNET S,BALDINI N.Mesenchymal stroma: Role in osteosarcoma progression [J].Cancer Lett,2017,405: 90-99.
[2] ROSEN G,MARCOVE R C,CAPARROS B,et al.Primary osteogenic sarcoma: the rationale for preoperative chemothe-rapy and delayed surgery [J].Cancer,1979,43(6): 2163-2177.
[3] GORLICK R,JANEWAY K,LESSNICK S,et al.Children's Oncology Group's 2013 blueprint for research: bone tumors [J].Pediatr Blood Cancer,2013,60(6): 1009-1015.
[4] HILL M,TRAN N.miRNA interplay: mechanisms and con-sequences in cancer [J].Dis Model Mech,2021,14(4): dmm047662.
[5] SALIMINEJAD K,KHORRAM KHORSHID H R,SOLEYMANI FARD S,et al.An overview of microRNAs: biology,functions,therapeutics,and analysis methods [J].J Cell Physiol,2019,234(5): 5451-5465.
[6] ANDERSEN G B,KNUDSEN A,HAGER H,et al.miRNA profiling identifies deregulated miRNAs associated with osteosarcoma development and time to metastasis in two large cohorts [J].Mol Oncol,2018,12(1): 114-131.
[7] CHANG Y H,HUANG Y L,TSAI H C,et al.Chemokine ligand 2 promotes migration in osteosarcoma by regulating the miR-3659/ MMP-3 Axis [J].Biomedicines,2023,11(10):2768.
[8] ZHENG C,LI R,ZHENG S,et al.The knockdown of lncRNA DLGAP1-AS2 suppresses osteosarcoma progression by inhibiting aerobic glycolysis via the miR-451a/HK2 axis [J].Cancer Sci,2023,114(12):4747-4762.
[9] SAADH M J,RASHED A B,JAMAL A,et al.miR-199a-3p suppresses neuroinflammation by directly targeting MyD88 in a mouse model of bone cancer pain [J].Life Sci,2023,333: 122139.
[10] ZHANG D,LIU X,LI Y,et al.LINC01189-miR-586-ZEB1 feedback loop regulates breast cancer progression through Wnt/beta-catenin signaling pathway [J].Mol Ther Nucleic Acids,2021,25: 455-467.
[11] LIU C,YANG J,ZHU F,et al.Exosomal circ_0001190 regulates the progression of gastric cancer via miR-586/SOSTDC1 axis [J].Biochem Genet,2022,60(6): 1895-1913.
[12] LUO Y,HOU W T,ZENG L,et al.Progress in the study of markers related to glioma prognosis [J].Eur Rev Med Pharmacol Sci,2020,24(14): 7690-7697.
[13] MOHAPATRA P,MADHULIKA S,BEHERA S,et al.Nimbolide-based nanomedicine inhibits breast cancer stem-like cells by epigenetic reprogramming of DNMTs-SFRP1-Wnt/β-catenin signaling axis [J].Mol Ther Nucleic Acids,2023,34: 102031.
[14] BAHARUDIN R,TIENG F Y F,LEE L H,et al.Epigenetics of SFRP1: the dual roles in human cancers[J].Cancers(Basel),2020,12(2): 445.
[15] ATSCHEKZEI F,HENNENLOTTER J,JANISCH S,et al.SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence[J].Epigenetics,2012,7(5): 447-457.
[16] HENG L,JIA Z,BAI J,et al.Molecular characterization of metastatic osteosarcoma: differentially expressed genes,transcription factors and microRNAs [J].Mol Med Rep,2017,15(5): 2829-2836.
[17] ALESSANDRINI L,MANCHI M,DE RE V,et al.Proposed molecular and miRNA classification of gastric cancer [J].Int J Mol Sci,2018,19(6): 1683.
[18] SABIT H,CEVIK E,TOMBULOGLU H,et al.Triple negative breast cancer in the era of miRNA [J].Crit Rev Oncol Hematol,2021,157: 103196.
[19] GHAFOURI-FARD S,HONARMAND TAMIZKAR K,HUSSEN B M,et al.MicroRNA signature in liver cancer [J].Pathol Res Pract,2021,219: 153369.
[20] 袁長深,容偉明,盧智賢,等.基于生物信息學構(gòu)建骨肉瘤miRNA-mRNA的調(diào)控網(wǎng)絡(luò)[J].中國組織工程研究,2021,25(17): 2740-2746.
相似文獻/References:
[1]許揚梅 龔福生 劉沁穎 劉施佳 黃麗潔 鄭秋紅.MiR-194過表達和抑制表達對肝癌細胞株Hep-3b中側(cè)群細胞增殖的影響[J].福建醫(yī)藥雜志,2019,41(06):141.
XU Yangmei,GONG Fusheng,LIU Qinying,et al.Influence of miR-194 up and down-expression on liver cancer stem cells[J].FUJIAN MEDICAL JOURNAL,2019,41(01):141.
[2]林文韜 王武煉 肖莉莉 張怡元.基于GEO數(shù)據(jù)庫發(fā)現(xiàn)骨肉瘤關(guān)鍵基因GMFG及其生物學功能[J].福建醫(yī)藥雜志,2020,42(02):112.
LIN Wentao,WANG Wulian,XIAO Lili,et al.Identification of the key gene GMFG and its biological function in osteosarcoma based on GEO database[J].FUJIAN MEDICAL JOURNAL,2020,42(01):112.
[3]肖莉莉 劉 暉 賈春鋒.基于核酸適配體的微流控芯片的構(gòu)建及對循環(huán)腫瘤細胞篩選性能的測定[J].福建醫(yī)藥雜志,2020,42(02):119.
[4]陳康堯,顧恩毅,蔡碰德,等.H1受體拮抗劑異丙嗪對順鉑治療骨肉瘤的影響及機制[J].福建醫(yī)藥雜志,2021,43(04):132.
CHEN Kangyao,GU Enyi,CAI Pengde,et al.Efficacy and mechanism of H1 receptor antagonist promethazine on osteosarcoma treated with cisplatin[J].FUJIAN MEDICAL JOURNAL,2021,43(01):132.
[5]鐘志輝,林焱斌,莊 研,等.骨肉瘤組織ACTN4和CD133的表達及其影響因素[J].福建醫(yī)藥雜志,2021,43(05):117.
ZHONG Zhihui,LIN Yanbin,ZHUANG Yan,et al.Expression and interfering factors of ACTN4 and CD133 in osteosarcoma[J].FUJIAN MEDICAL JOURNAL,2021,43(01):117.
[6]林東澤.shRNA沉默c-myc基因?qū)G-63骨肉瘤細胞c-myc/PD-L1軸的影響[J].福建醫(yī)藥雜志,2022,44(05):133.